Strong product innovation, market share gains, and demographic trends position the company for sustained expansion, while operational improvements and strategic R&D investments support long-term margin growth. Growing demand in major markets and effective pricing increases in cardiovascular segments, combined with expansion in China and high-margin consumables, are boosting profitability and cash flow.
Cyborg Score Rationale
Terumo demonstrates strong fundamentals with diversified medical device portfolio, consistent revenue growth, and strategic positioning in high-demand markets. However, pricing pressures and competitive consolidation in the industry present ongoing headwinds.
Top Insights
Cardiac and vascular segment dominates at 60%+ of revenue, providing focused competitive advantage in high-growth interventional markets
North America-heavy revenue concentration (38%) provides stability but geographic diversification remains a growth opportunity
Recent earnings calls indicate record revenue achievement with Q3 2025 performance, demonstrating momentum
Strategic R&D investments and operational efficiency initiatives support margin expansion amid commodity and pricing pressures
Named Competitors
Medtronic — Diversified medical device and healthcare solutions
Boston Scientific — Vascular and interventional medical devices
Merit Medical Systems — Specialty medical devices
Recent Developments
(March 2024) Terumo Blood and Cell Technologies partners with CiRA Foundation for automated iPS cell manufacturing
(February 2024) International consensus recommendations published for pregnancy complications in sickle cell disease patients
(February 2025) Q3 2025 earnings conference call highlights record revenue and strategic growth initiatives
Open the full interactive Terumo Corporation report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.